Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
about
The endothelium abridges insulin resistance to premature agingContinued efforts to translate diabetes cardiovascular outcome trials into clinical practiceRecent Advances in Disease Modeling and Drug Discovery for Diabetes Mellitus Using Induced Pluripotent Stem CellsAtrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectivesPeripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomesPolyphenol Stilbenes: Molecular Mechanisms of Defence against Oxidative Stress and Aging-Related DiseasesType-2 diabetes: Current understanding and future perspectivesMagnetic resonance imaging and multi-detector computed tomography assessment of extracellular compartment in ischemic and non-ischemic myocardial pathologiesThe role of oxidative stress and inflammation in cardiovascular agingThe perils of surrogate endpointsGlucose induces sensitivity to oxygen deprivation and modulates insulin/IGF-1 signaling and lipid biosynthesis in Caenorhabditis elegans.Comparison of coronary plaque, coronary artery calcification and major adverse cardiac events in Chinese outpatients with and without type 2 diabetesPathogenesis of diabetic cerebral vascular disease complicationPotential Role of Protein Disulfide Isomerase in Metabolic Syndrome-Derived Platelet HyperactivityType 1 diabetes mellitus.Glucose or Altered Ceramide Biosynthesis Mediate Oxygen Deprivation Sensitivity Through Novel Pathways Revealed by Transcriptome Analysis in Caenorhabditis elegans.Predictors of epicardial adipose tissue in patients with type 2 diabetes mellitus.Vinpocetine attenuates neointimal hyperplasia in diabetic rat carotid arteries after balloon injury.Comparative effects of carbohydrate versus fat restriction on metabolic profiles, biomarkers of inflammation and oxidative stress in overweight patients with Type 2 diabetic and coronary heart disease: A randomized clinical trialSGLT2 inhibitors as add on therapy in type 2 diabetes: a real world studyMolecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes.MicroRNA-146a decreases high glucose/thrombin-induced endothelial inflammation by inhibiting NAPDH oxidase 4 expressionBiomarkers of endothelial dysfunction in relation to impaired carbohydrate metabolism following pregnancy with gestational diabetes mellitusVariable reactive hyperemia in normotensive strains of ratAxl as a mediator of cellular growth and survivalPlatelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation.Activation of κ-opioid receptor by U50,488H improves vascular dysfunction in streptozotocin-induced diabetic rats.Fibroblast growth factor-9 enhances M2 macrophage differentiation and attenuates adverse cardiac remodeling in the infarcted diabetic heartRole of oxidative stress in endothelial insulin resistance.Association between metabolic syndrome and pelvic organ prolapse severity.Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage.Beneficial effect of troxerutin on diabetes-induced vascular damages in rat aorta: histopathological alterations and antioxidation mechanismMedication and Dietary Supplement Interactions among a Low-Income, Hospitalized Patient Population Who Take Cardiac Medications.Protective role of insulin-like growth factor-1 receptor in endothelial cells against unilateral ureteral obstruction-induced renal fibrosis.Chronic Inhibition of PDE5 Limits Pro-Inflammatory Monocyte-Macrophage Polarization in Streptozotocin-Induced Diabetic MiceAssociation of elevated apoA-I glycation and reduced HDL-associated paraoxonase1, 3 activity, and their interaction with angiographic severity of coronary artery disease in patients with type 2 diabetes mellitusIncreased plasma BMP-2 levels are associated with atherosclerosis burden and coronary calcification in type 2 diabetic patientsC-Peptide Is Independently Associated with an Increased Risk of Coronary Artery Disease in T2DM Subjects: A Cross-Sectional StudyAtazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitusUp-Regulation of CREG Expression by the Transcription Factor GATA1 Inhibits High Glucose- and High Palmitate-Induced Apoptosis in Human Umbilical Vein Endothelial Cells.
P2860
Q24605364-700CD379-3AFE-4D65-9B40-91949027A07AQ26741860-B675BEEE-8F36-4AE2-80A1-7605CBD58CDEQ26767096-F2D53BC9-FC1B-433A-9F9D-EFC1A0BF4B90Q26778659-6E256B4F-9C64-4128-B049-2662B6A56DAAQ26799591-3A560B14-47DE-45AE-A89A-11C40F154180Q26800956-2ADA9314-86F7-4F19-BE0A-8033A259AB6BQ26801324-4476CAC6-46F0-4EE8-B993-311C4A856189Q26824231-E2E8FA50-50C8-4AD2-99DE-3877D7CC6C7FQ26864987-76609179-357A-465A-B9E4-33281633862EQ27025740-FC6EE6D2-8815-4D43-AE8E-6B491AE53E9FQ27346465-F9FEAE94-B1FA-482D-AEB1-D39C6B7D4D58Q28067194-EA2732FE-202C-4412-A7E8-A4FD7D986459Q28087462-06C32073-8E12-4F30-9E64-B8B1C3899B86Q28354107-B4E91315-82C0-4A47-A074-07A6E4C1208CQ30235021-535CB973-F8C5-476B-AC95-00F03BFEDED8Q30823934-E7F04382-3713-4DEB-86E9-3F417B30DCF9Q33599279-D54E8ED2-71C4-488C-A540-4A24834F3C38Q33599923-21F346FF-3517-4F46-92F0-29F7385A7A3BQ33756447-1CF1B732-CCA7-409A-B0FF-2E2585B403B1Q33859212-37529EFB-70F9-4C68-92E3-9FAA65ACF009Q34099937-41A789D6-2277-4FEA-AF2C-44CE960DC65CQ34266384-E267B51B-EDA4-49C3-BA20-688C5A5FC213Q34340112-5158A31D-A5C4-4E66-A123-B37B7B6F0B52Q34400004-DFA0F942-8272-45A1-8A04-B3E62ED78327Q34619118-BDFF72D6-FBEF-4082-99FB-2345C6466B3CQ34816571-1D46E1EA-39A8-48D0-BCC8-D1073170F923Q35166507-5EF59A17-9AF2-46C9-8F95-4779FABD8460Q35175715-7E366D82-0BEF-4D4C-A76C-2DA2340BC213Q35179243-EC5A73FE-78DE-47CB-BB5F-39D01E931100Q35212239-264554E0-EB8B-4EFE-9D00-0194466AB623Q35249824-BDCCFDD4-DAD2-406D-8629-EF67B99211EDQ35278126-5B5E13EC-DC85-4AD9-9349-BAA47A651C65Q35531055-E8CC83DD-693E-43D7-B027-B127A4042DEDQ35568112-5118845A-C159-4C35-9B80-0E6DD0351D12Q35593122-63B9B1B5-97FE-4E45-B8EC-998F9C0CEB37Q35610045-A2CCEFF8-AE11-4A52-A534-DE032762458BQ35670515-BC7C67C0-9D04-47FB-98E7-DE7D7B7DE09DQ35670690-1B472469-0463-4364-8591-DF3497CC0366Q35832866-6979AC32-56DF-4F8D-A8A4-B98254242076Q36006817-A4824A1F-0BC0-4E35-8DB7-70DD4C365D5F
P2860
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Diabetes and vascular disease: ...... s, and medical therapy: part I
@en
Diabetes and vascular disease: ...... s, and medical therapy: part I
@nl
type
label
Diabetes and vascular disease: ...... s, and medical therapy: part I
@en
Diabetes and vascular disease: ...... s, and medical therapy: part I
@nl
prefLabel
Diabetes and vascular disease: ...... s, and medical therapy: part I
@en
Diabetes and vascular disease: ...... s, and medical therapy: part I
@nl
P2860
P921
P356
P1476
Diabetes and vascular disease: ...... s, and medical therapy: part I
@en
P2093
Francesco Paneni
Mark A Creager
P2860
P304
P356
10.1093/EURHEARTJ/EHT149
P5008
P577
2013-05-02T00:00:00Z